Literature DB >> 15136638

Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.

Nai-Kong V Cheung1, Shakeel Modak, Yukang Lin, Hongfen Guo, Pat Zanzonico, John Chung, Yuting Zuo, James Sanderson, Sibylle Wilbert, Louis J Theodore, Donald B Axworthy, Steven M Larson.   

Abstract

UNLABELLED: Multistep targeting can improve the therapeutic index of antibody-based targeting, particularly relevant to pediatric tumors where acute toxicity and late effects of treatment are major concerns. Neuroblastoma is uniquely suited for such investigations because of its abundance of surface ganglioside GD2.
METHODS: 5F11scFv (scFv = single-chain variable fragment) was constructed from the variable regions of the heavy (V(H)) and kappa-light (V(L)) chain complementary DNA (cDNA) of anti-GD2 IgM hybridoma 5F11 and ligated to full-length streptavidin cDNA for expression in Escherichia coli. Purified 5F11-scFv-streptavidin (5F11-scFv-SA) was a homotetramer and showed comparable avidity to 5F11 IgM and a 30-fold improvement over monomeric scFv. Biodistribution of 5F11-scFv-SA was studied in nude mice xenografted with neuroblastoma LAN-1. Twenty-four hours after intravenous injection of 300-900 microg 5F11-scFv-SA, 150-450 microg of a thiogalactoside-containing clearing agent, (Gal-NAc)(16)-alpha-S-C(5)H(10)-NH-LC-N-Me-biotin (molecular weight, 8652), were administered intravenously, followed by approximately 2.5 microg (1.85-3.7 MBq) (111)In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-biotin ((111)In-DOTA-biotin) intravenously 4 h later and clocked as time 0.
RESULTS: Tumor uptake (percentage of injected dose per gram [%ID/g]) at 2 h was 7 %ID/g and decayed with a half-life of 72 h, whereas blood %ID/g rapidly decreased to <1/500 of that of tumor after the first 24 h. The tumor-to-nontumor (T/NT) ratio at 72 h was high (median, 106; range, 3.4 [kidney] to 1660 [blood]). When the area under the radioactivity curve was computed, the T/NT organ ratio was favorable (4.8 for kidney and 162 for blood). When human and murine tumors were surveyed, the T/NT ratio of (111)In-DOTA-biotin uptake correlated with their levels of GD2 expression as assayed by flow cytometry. Biotinylated polypeptides (bovine serum albumin and vasointestinal peptides) achieved selective tumor targeting when the multistep strategy was applied.
CONCLUSION: Improvement in the T/NT ratio using pretargeting strategy may increase the efficacy and safety of scFv-based approaches in cancer therapy. Additionally, since biotinylated polypeptides can be rendered tumor selective, a large repertoire of agents can potentially be explored.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136638

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  25 in total

1.  Antibody-based cancer therapies: back to "polyclonals"?

Authors:  Giovanni Paganelli; Rita De Santis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-17       Impact factor: 9.236

2.  Complexes of streptavidin-fused antigens with biotinylated antibodies targeting receptors on dendritic cell surface: a novel tool for induction of specific T-cell immune responses.

Authors:  Ondrej Stanek; Irena Linhartova; Laleh Majlessi; Claude Leclerc; Peter Sebo
Journal:  Mol Biotechnol       Date:  2012-07       Impact factor: 2.695

3.  Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.

Authors:  Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 4.  Anti-GD2 antibody therapy for GD2-expressing tumors.

Authors:  Fariba Navid; Victor M Santana; Raymond C Barfield
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

Review 5.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 6.  Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.

Authors:  Dana L Casey; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2020-02       Impact factor: 11.151

Review 7.  Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Authors:  Zulmarie Perez Horta; Jacob L Goldberg; Paul M Sondel
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

Review 8.  Anti-GD2 immunotherapy for neuroblastoma.

Authors:  Sameer Sait; Shakeel Modak
Journal:  Expert Rev Anticancer Ther       Date:  2017-08-14       Impact factor: 4.512

9.  Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs.

Authors:  Jian Hu; Nai-Kong V Cheung
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

10.  Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.

Authors:  Chun-Yen Tsao; Francesco Sabbatino; Nai-Kong V Cheung; Jeff Chi-Feng Hsu; Vincenzo Villani; Xinhui Wang; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.